Araştırma Makalesi
BibTex RIS Kaynak Göster

Yıl 2020, Cilt: 2 Sayı: 1, 11 - 18, 29.01.2020

Emel Isiktas Sayilar Alparslan Ersoy Sedat Çelikçi Yavuz Ayar Fahir Özkalemkaş Vildan Ozkocaman Rıdvan Ali

https://doi.org/10.46310/tjim.655091
Cited By: 1

Öz

Teşekkür

çok teşekkür ederiz

Kaynakça

  • Zafrani L, Truffaut L, Kreis H, Etienne D, Rafat C, Lechaton S, Anglicheau D, Zuber J, Ciroldi M, Thervet E, Snanoudj R, Mamzer MF, Martinez F, Timsit MO, Bergougnoux L, Legendre C. Incidence, risk factors and clinical consequences of neutropenia following kidney transplantation: a retrospective study. Am J Transplant. 2009 Aug;9(8):1816-25. doi: 10.1111/j.1600-6143.2009.02699.x.
  • Hurst FP, Belur P, Nee R, Agodoa LY, Patel P, Abbott KC, Jindal RM. Poor outcomes associated with neutropenia after kidney transplantation: analysis of United States Renal Data System. Transplantation. 2011 Jul 15;92(1):36-40. doi: 10.1097/TP.0b013e31821c1e70.
  • Brennan DC, Flavin K, Lowell JA, Howard TK, Shenoy S, Burgess S, Dolan S, Kano JM, Mahon M, Schnitzler MA, Woodward R, Irish W, Ramachamdra V, Singer GG. Leukocyte response to thymoglobulin or atgam for induction immunosuppression in a randomized, double-blind clinical trial in renal transplant recipients. Transplant Proc. 1999 May;31(3B Suppl):16S-18S.
  • Moreso F, Serón D, Morales JM, Cruzado JM, Gil-Vernet S, Pérez JL, Fulladosa X, Andrés A, Grinyó JM. Incidence of leukopenia and cytomegalovirus disease in kidney transplants treated with mycophenolate mofetil combined with low cyclosporine and steroid doses. Clin Transplant. 1998 Jun;12(3):198-205.
  • Hong JC, Kahan BD. Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management. Transplantation. 2000 May 27;69(10):2085-90.
  • Taber DJ, Ashcraft E, Baillie GM, Berkman S, Rogers J, Baliga PK, Rajagopalan PR, Lin A, Emovon O, Afzal F, Chavin KD. Valganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus disease. Transpl Infect Dis. 2004 Sep;6(3):101-9. Keles M, Yildirim R, Uyanik A, Turkmen M, Bilen Y, Aydinli B, Cetinkaya R, Polat KY. Neutropenia related to valacyclovir and valganciclovir in 2 renal transplant patients and treatment with granulocyte colony stimulating factor: a case report. Exp Clin Transplant. 2010 Jun;8(2):181-3.
  • Kutsogiannis DJ, Crowther MA, Lazarovits AI. Granulocyte macrophage colony-stimulating factor for the therapy of cytomegalovirus and ganciclovir-induced leukopenia in a renal transplant recipient. Transplantation. 1992 Apr;53(4):930-2.
  • Bradley PP, Warden GD, Maxwell JG, Rothstein G. Neutropenia and thrombocytopenia in renal allograft recipients treated with trimethoprim-sulfamethoxazole. Ann Intern Med. 1980 Oct;93(4):560-2.
  • Derici U, Ayerdem F, Arinsoy T, Reis KA, Dalgic A, Sindel S. The use of granulocyte colony-stimulating factor in a neutropenic renal transplant recipient. Haematologia (Budap). 2002;32(4):557-60.
  • Matsui K, Shibagaki Y, Sasaki H, Chikaraishi T, Yasuda T, Kimura K. Mycophenolate mofetil-induced agranulocytosis in a renal transplant recipient. Clin Exp Nephrol. 2010 Dec;14(6):637-40. doi: 10.1007/s10157-010-0323-y.
  • Savvidaki E, Kazakopoulos P, Papachristou E, Karavias D, Zavvos V, Voliotis G, Kalliakmani P, Marangos M, Goumenos DS. Replacement of mycophenolate acid with everolimus in patients who became neutropenic after renal transplant. Exp Clin Transplant. 2014 Feb;12(1):31-6.
  • De Rycke A, Dierickx D, Kuypers DR. Tacrolimus-induced neutropenia in renal transplant recipients. Clin J Am Soc Nephrol. 2011 Mar;6(3):690-4. doi: 10.2215/CJN.07320810.
  • Schmaldienst S, Bekesi G, Deicher R, Franz M, Hörl WH, Pohanka E. Recombinant human granulocyte colony-stimulating factor after kidney transplantation: a retrospective analysis to evaluate the benefit or risk of immunostimulation. Transplantation. 2000 Feb 27;69(4):527-31.
  • Page B, Morin MP, Mamzer MF, Thervet E, Legendre C. Use of granulocyte-macrophage colony-stimulating factor in leukopenic renal transplant recipients. Transplant Proc. 1994 Feb;26(1):283.
  • Hashmi A, Hussain M, Hussain Z, Ahmed E, Shamsi T, Naqvi R, Ali B, Mehdi H, Mohsin R, Naqvi A, Rizvi A. Use of rHu GM-CSF in renal-transplant patients developing leukopenia. Transplant Proc. 1997 Nov;29(7):3053.
  • Birkeland SA, Elbirk A, Rohr N, Jørgensen KA. Severe neutropenia after renal transplantation and its reversal with granulocyte colony-stimulating factor. Transplant Proc. 1994 Dec;26(6):3098-9.
  • Moghal NE, Milford DV, Darbyshire P. Treatment of neutropenia in a renal transplant recipient with granulocyte colony-stimulating factor. Pediatr Nephrol. 1998 Jan;12(1):14-5.
  • Matsui K, Shibagaki Y, Sasaki H, Chikaraishi T, Yasuda T, Kimura K. Mycophenolate mofetil-induced agranulocytosis in a renal transplant recipient. Clin Exp Nephrol. 2010 Dec;14(6):637-40. doi: 10.1007/s10157-010-0323-y.
  • Peddi VR, Hariharan S, Schroeder TJ, First MR. Role of granulocyte colony stimulating factor (G-CSF) in reversing neutropenia in renal allograft recipients. Clin Transplant. 1996 Feb;10(1 Pt 1):20-3.
  • Hartmann EL, Gatesman M, Roskopf-Somerville J, Stratta R, Farney A, Sundberg A. Management of leukopenia in kidney and pancreas transplant recipients. Clin Transplant. 2008 Nov-Dec;22(6):822-8. doi: 10.1111/j.1399-0012.2008.00893.x.
  • Page AV, Liles WC. Granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, and other immunomodulatory therapies for the treatment of infectious diseases in solid organ transplant recipients. Curr Opin Organ Transplant. 2008 Dec;13(6):575-80. doi: 10.1097/MOT.0b013e3283186b80.
  • Mavrakanas TA, Fournier MA, Clairoux S, Amiel JA, Tremblay ME, Vinh DC, Coursol C, Thirion DJG, Cantarovich M. Neutropenia in kidney and liver transplant recipients: Risk factors and outcomes. Clin Transplant. 2017 Oct;31(10). doi: 10.1111/ctr.13058.
  • Turgeon N, Hovingh GK, Fishman JA, Basgoz N, Tolkoff-Rubin NE, Doran M, Cosimi AB, Rubin RH. Safety and efficacy of granulocyte colony-stimulating factor in kidney and liver transplant recipients. Transpl Infect Dis. 2000 Mar;2(1):15-21.
  • Brum S, Nolasco F, Sousa J, Ferreira A, Possante M, Pinto JR, Barroso E, Santos JR. Leukopenia in kidney transplant patients with the association of valganciclovir and mycophenolate mofetil. Transplant Proc. 2008 Apr;40(3):752-4. doi: 10.1016/j.transproceed.2008.02.048.
  • Tajima A, Aso Y, Kawabe K, Suzuki K, Ohtawara Y, Ohta N, Hata M, Nakano M, Ushiyama T, Ueda D. Colony-stimulating factor for treatment of leukopenia after kidney allografting. Transplant Proc. 1991 Feb;23(1 Pt 2):1369-70.
  • Becker-Cohen R, Ben-Shalom E, Rinat C, Feinstein S, Geylis M, Frishberg Y. Severe neutropenia in children after renal transplantation: incidence, course, and treatment with granulocyte colony-stimulating factor. Pediatr Nephrol. 2015 Nov;30(11):2029-36. doi: 10.1007/s00467-015-3113-7.
  • Squiers EC, Elkhammas EA, Henry ML. Use of granulocyte-macrophage colony-stimulating factor for reversal of neutropenia following combined kidney-pancreas transplantation. Transplant Proc. 1995 Dec;27(6):3092-3.
  • Hamel S, Kuo V, Sawinski D, Johnson D, Bloom RD, Bleicher M, Goral S, Lim MA, Trofe-Clark J. Single-center, real-world experience with granulocyte colony-stimulating factor for management of leukopenia following kidney transplantation. Clin Transplant. 2019 Jun;33(6):e13541. doi: 10.1111/ctr.13541.
  • Poon T, Guerra CM. Evaluation of Filgrastim Therapy in Kidney Transplant Recipients. Transplant. 2017 Dec;27(4):360-364. doi: 10.1177/1526924817731880.
  • Foster PF, Mital D, Sankary HN, McChesney LP, Marcon J, Koukoulis G, Kociss K, Leurgans S, Whiting JF, Williams JW. The use of granulocyte colony-stimulating factor after liver transplantation. Transplantation. 1995 Jun 15;59(11):1557-63.
  • Foster PF, Kociss K, Shen J, Sankary HN, Mital D, Chong AS, Xiao F, Williams JW. Granulocyte colony-stimulating factor immunomodulation in the rat cardiac transplantation model. Transplantation. 1996 Apr 15;61(7):1122-5.
  • Knoll GA, MacDonald I, Khan A, Van Walraven C. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol. 2003 Sep;14(9):2381-6.
  • Vanhove T, Kuypers D, Claes KJ, Evenepoel P, Meijers B, Naesens M, Vanrenterghem Y, Cornelis T, Bammens B. Reasons for dose reduction of mycophenolate mofetil during the first year after renal transplantation and its impact on graft outcome. Transpl Int. 2013 Aug;26(8):813-21. doi: 10.1111/tri.12133.
  • Cattaneo D, Perico N, Gaspari F, Gotti E, Remuzzi G. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int. 2002 Sep;62(3):1060-7.
  • Minguez C, Mazuecos A, Ceballos M, Tejuca F, Rivero M. Worsening of renal function in a renal transplant patient treated with granulocyte colony-stimulating factor. Nephrol Dial Transplant. 1995 Nov;10(11):2166-7.
  • Anupama PH, Abraham G, Koshy P, Mathew M, George DS. Filgrastim-related acute kidney injury in a male renal transplant recipient. Saudi J Kidney Dis Transpl. 2018 May-Jun;29(3):739-740. doi: 10.4103/1319-2442.235196.
  • Colquhoun SD, Shaked A, Jurim O, Colonna JO, Rosove MH, Busuttil RW. Reversal of neutropenia with granulocyte colony-stimulating factor without precipitating liver allograft rejection. Transplantation. 1993 Dec;56(6):1593-5).
  • Nishida M, Hamaoka K. How does G-CSF act on the kidney during acute tubular injury? Nephron Exp Nephrol. 2006;104(4):e123-8.
  • Arora S, Bhargava A, Jasnosz K, Clark B. Relapsing acute kidney injury associated with pegfilgrastim. Case Rep Nephrol Urol. 2012 Jul;2(2):165-71. doi: 10.1159/000345278.
  • Tigue CC, McKoy JM, Evens AM, Trifilio SM, Tallman MS, Bennett CL. Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant. 2007 Aug;40(3):185-92.
  • Johnson DW, Herzig KA. Clinical appearance of a post-transplant lymphoma following G-CSF therapy. Nephrol Dial Transplant. 1999 Jul;14(7):1806-7.

Granulocyte colony-stimulating factor usage in drug-induced neutropenia after kidney transplantation: a single-center experience

Yıl 2020, Cilt: 2 Sayı: 1, 11 - 18, 29.01.2020

Emel Isiktas Sayilar Alparslan Ersoy Sedat Çelikçi Yavuz Ayar Fahir Özkalemkaş Vildan Ozkocaman Rıdvan Ali

https://doi.org/10.46310/tjim.655091
Cited By: 1

Öz

Introduction. Granulocyte colony-stimulating factor (G-CSF) therapy is commonly used in kidney and liver transplant recipients with severe neutropenia. However, rapid and high increases in neutrophil counts of some patients may occur during treatment. This retrospective study aimed to determine the efficacy and safety of G-CSF treatment in neutropenic kidney transplant recipients.
Methods. Eight kidney transplant recipients treated with G-CSF for drug-induced neutropenia (neutrophil count <1000 cells/µL) were included in the study. Daily renal function tests, leukocyte (WBC) and absolute neutrophil counts were measured.
Results. The median duration of G-CSF treatment was 4 days (2-5). The median WBC and neutrophil counts elevated from 1130 and 565 cells/μL to 4400 and 1950 cells/μL after treatment, respectively (p=0.012). The median peak WBC and neutrophil counts during treatment were 18,045 and 16,445 cells/μL, respectively. The WBC counts returned to normal limits after a median of 22 days from the maximum value. No acute rejection was observed within three months of discontinuation of treatment.
Conclusions. G-CSF may be a useful therapeutic alternative for kidney recipients with severe neutropenia. It seems reasonable to withdraw G-CSF treatment when WBC and neutrophil counts reach certain cut-off values during treatment.

Anahtar Kelimeler

Filgrastim granulocyte colony-stimulating factor kidney transplantation leukopenia neutropenia

Kaynakça

  • Zafrani L, Truffaut L, Kreis H, Etienne D, Rafat C, Lechaton S, Anglicheau D, Zuber J, Ciroldi M, Thervet E, Snanoudj R, Mamzer MF, Martinez F, Timsit MO, Bergougnoux L, Legendre C. Incidence, risk factors and clinical consequences of neutropenia following kidney transplantation: a retrospective study. Am J Transplant. 2009 Aug;9(8):1816-25. doi: 10.1111/j.1600-6143.2009.02699.x.
  • Hurst FP, Belur P, Nee R, Agodoa LY, Patel P, Abbott KC, Jindal RM. Poor outcomes associated with neutropenia after kidney transplantation: analysis of United States Renal Data System. Transplantation. 2011 Jul 15;92(1):36-40. doi: 10.1097/TP.0b013e31821c1e70.
  • Brennan DC, Flavin K, Lowell JA, Howard TK, Shenoy S, Burgess S, Dolan S, Kano JM, Mahon M, Schnitzler MA, Woodward R, Irish W, Ramachamdra V, Singer GG. Leukocyte response to thymoglobulin or atgam for induction immunosuppression in a randomized, double-blind clinical trial in renal transplant recipients. Transplant Proc. 1999 May;31(3B Suppl):16S-18S.
  • Moreso F, Serón D, Morales JM, Cruzado JM, Gil-Vernet S, Pérez JL, Fulladosa X, Andrés A, Grinyó JM. Incidence of leukopenia and cytomegalovirus disease in kidney transplants treated with mycophenolate mofetil combined with low cyclosporine and steroid doses. Clin Transplant. 1998 Jun;12(3):198-205.
  • Hong JC, Kahan BD. Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management. Transplantation. 2000 May 27;69(10):2085-90.
  • Taber DJ, Ashcraft E, Baillie GM, Berkman S, Rogers J, Baliga PK, Rajagopalan PR, Lin A, Emovon O, Afzal F, Chavin KD. Valganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus disease. Transpl Infect Dis. 2004 Sep;6(3):101-9. Keles M, Yildirim R, Uyanik A, Turkmen M, Bilen Y, Aydinli B, Cetinkaya R, Polat KY. Neutropenia related to valacyclovir and valganciclovir in 2 renal transplant patients and treatment with granulocyte colony stimulating factor: a case report. Exp Clin Transplant. 2010 Jun;8(2):181-3.
  • Kutsogiannis DJ, Crowther MA, Lazarovits AI. Granulocyte macrophage colony-stimulating factor for the therapy of cytomegalovirus and ganciclovir-induced leukopenia in a renal transplant recipient. Transplantation. 1992 Apr;53(4):930-2.
  • Bradley PP, Warden GD, Maxwell JG, Rothstein G. Neutropenia and thrombocytopenia in renal allograft recipients treated with trimethoprim-sulfamethoxazole. Ann Intern Med. 1980 Oct;93(4):560-2.
  • Derici U, Ayerdem F, Arinsoy T, Reis KA, Dalgic A, Sindel S. The use of granulocyte colony-stimulating factor in a neutropenic renal transplant recipient. Haematologia (Budap). 2002;32(4):557-60.
  • Matsui K, Shibagaki Y, Sasaki H, Chikaraishi T, Yasuda T, Kimura K. Mycophenolate mofetil-induced agranulocytosis in a renal transplant recipient. Clin Exp Nephrol. 2010 Dec;14(6):637-40. doi: 10.1007/s10157-010-0323-y.
  • Savvidaki E, Kazakopoulos P, Papachristou E, Karavias D, Zavvos V, Voliotis G, Kalliakmani P, Marangos M, Goumenos DS. Replacement of mycophenolate acid with everolimus in patients who became neutropenic after renal transplant. Exp Clin Transplant. 2014 Feb;12(1):31-6.
  • De Rycke A, Dierickx D, Kuypers DR. Tacrolimus-induced neutropenia in renal transplant recipients. Clin J Am Soc Nephrol. 2011 Mar;6(3):690-4. doi: 10.2215/CJN.07320810.
  • Schmaldienst S, Bekesi G, Deicher R, Franz M, Hörl WH, Pohanka E. Recombinant human granulocyte colony-stimulating factor after kidney transplantation: a retrospective analysis to evaluate the benefit or risk of immunostimulation. Transplantation. 2000 Feb 27;69(4):527-31.
  • Page B, Morin MP, Mamzer MF, Thervet E, Legendre C. Use of granulocyte-macrophage colony-stimulating factor in leukopenic renal transplant recipients. Transplant Proc. 1994 Feb;26(1):283.
  • Hashmi A, Hussain M, Hussain Z, Ahmed E, Shamsi T, Naqvi R, Ali B, Mehdi H, Mohsin R, Naqvi A, Rizvi A. Use of rHu GM-CSF in renal-transplant patients developing leukopenia. Transplant Proc. 1997 Nov;29(7):3053.
  • Birkeland SA, Elbirk A, Rohr N, Jørgensen KA. Severe neutropenia after renal transplantation and its reversal with granulocyte colony-stimulating factor. Transplant Proc. 1994 Dec;26(6):3098-9.
  • Moghal NE, Milford DV, Darbyshire P. Treatment of neutropenia in a renal transplant recipient with granulocyte colony-stimulating factor. Pediatr Nephrol. 1998 Jan;12(1):14-5.
  • Matsui K, Shibagaki Y, Sasaki H, Chikaraishi T, Yasuda T, Kimura K. Mycophenolate mofetil-induced agranulocytosis in a renal transplant recipient. Clin Exp Nephrol. 2010 Dec;14(6):637-40. doi: 10.1007/s10157-010-0323-y.
  • Peddi VR, Hariharan S, Schroeder TJ, First MR. Role of granulocyte colony stimulating factor (G-CSF) in reversing neutropenia in renal allograft recipients. Clin Transplant. 1996 Feb;10(1 Pt 1):20-3.
  • Hartmann EL, Gatesman M, Roskopf-Somerville J, Stratta R, Farney A, Sundberg A. Management of leukopenia in kidney and pancreas transplant recipients. Clin Transplant. 2008 Nov-Dec;22(6):822-8. doi: 10.1111/j.1399-0012.2008.00893.x.
  • Page AV, Liles WC. Granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, and other immunomodulatory therapies for the treatment of infectious diseases in solid organ transplant recipients. Curr Opin Organ Transplant. 2008 Dec;13(6):575-80. doi: 10.1097/MOT.0b013e3283186b80.
  • Mavrakanas TA, Fournier MA, Clairoux S, Amiel JA, Tremblay ME, Vinh DC, Coursol C, Thirion DJG, Cantarovich M. Neutropenia in kidney and liver transplant recipients: Risk factors and outcomes. Clin Transplant. 2017 Oct;31(10). doi: 10.1111/ctr.13058.
  • Turgeon N, Hovingh GK, Fishman JA, Basgoz N, Tolkoff-Rubin NE, Doran M, Cosimi AB, Rubin RH. Safety and efficacy of granulocyte colony-stimulating factor in kidney and liver transplant recipients. Transpl Infect Dis. 2000 Mar;2(1):15-21.
  • Brum S, Nolasco F, Sousa J, Ferreira A, Possante M, Pinto JR, Barroso E, Santos JR. Leukopenia in kidney transplant patients with the association of valganciclovir and mycophenolate mofetil. Transplant Proc. 2008 Apr;40(3):752-4. doi: 10.1016/j.transproceed.2008.02.048.
  • Tajima A, Aso Y, Kawabe K, Suzuki K, Ohtawara Y, Ohta N, Hata M, Nakano M, Ushiyama T, Ueda D. Colony-stimulating factor for treatment of leukopenia after kidney allografting. Transplant Proc. 1991 Feb;23(1 Pt 2):1369-70.
  • Becker-Cohen R, Ben-Shalom E, Rinat C, Feinstein S, Geylis M, Frishberg Y. Severe neutropenia in children after renal transplantation: incidence, course, and treatment with granulocyte colony-stimulating factor. Pediatr Nephrol. 2015 Nov;30(11):2029-36. doi: 10.1007/s00467-015-3113-7.
  • Squiers EC, Elkhammas EA, Henry ML. Use of granulocyte-macrophage colony-stimulating factor for reversal of neutropenia following combined kidney-pancreas transplantation. Transplant Proc. 1995 Dec;27(6):3092-3.
  • Hamel S, Kuo V, Sawinski D, Johnson D, Bloom RD, Bleicher M, Goral S, Lim MA, Trofe-Clark J. Single-center, real-world experience with granulocyte colony-stimulating factor for management of leukopenia following kidney transplantation. Clin Transplant. 2019 Jun;33(6):e13541. doi: 10.1111/ctr.13541.
  • Poon T, Guerra CM. Evaluation of Filgrastim Therapy in Kidney Transplant Recipients. Transplant. 2017 Dec;27(4):360-364. doi: 10.1177/1526924817731880.
  • Foster PF, Mital D, Sankary HN, McChesney LP, Marcon J, Koukoulis G, Kociss K, Leurgans S, Whiting JF, Williams JW. The use of granulocyte colony-stimulating factor after liver transplantation. Transplantation. 1995 Jun 15;59(11):1557-63.
  • Foster PF, Kociss K, Shen J, Sankary HN, Mital D, Chong AS, Xiao F, Williams JW. Granulocyte colony-stimulating factor immunomodulation in the rat cardiac transplantation model. Transplantation. 1996 Apr 15;61(7):1122-5.
  • Knoll GA, MacDonald I, Khan A, Van Walraven C. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol. 2003 Sep;14(9):2381-6.
  • Vanhove T, Kuypers D, Claes KJ, Evenepoel P, Meijers B, Naesens M, Vanrenterghem Y, Cornelis T, Bammens B. Reasons for dose reduction of mycophenolate mofetil during the first year after renal transplantation and its impact on graft outcome. Transpl Int. 2013 Aug;26(8):813-21. doi: 10.1111/tri.12133.
  • Cattaneo D, Perico N, Gaspari F, Gotti E, Remuzzi G. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int. 2002 Sep;62(3):1060-7.
  • Minguez C, Mazuecos A, Ceballos M, Tejuca F, Rivero M. Worsening of renal function in a renal transplant patient treated with granulocyte colony-stimulating factor. Nephrol Dial Transplant. 1995 Nov;10(11):2166-7.
  • Anupama PH, Abraham G, Koshy P, Mathew M, George DS. Filgrastim-related acute kidney injury in a male renal transplant recipient. Saudi J Kidney Dis Transpl. 2018 May-Jun;29(3):739-740. doi: 10.4103/1319-2442.235196.
  • Colquhoun SD, Shaked A, Jurim O, Colonna JO, Rosove MH, Busuttil RW. Reversal of neutropenia with granulocyte colony-stimulating factor without precipitating liver allograft rejection. Transplantation. 1993 Dec;56(6):1593-5).
  • Nishida M, Hamaoka K. How does G-CSF act on the kidney during acute tubular injury? Nephron Exp Nephrol. 2006;104(4):e123-8.
  • Arora S, Bhargava A, Jasnosz K, Clark B. Relapsing acute kidney injury associated with pegfilgrastim. Case Rep Nephrol Urol. 2012 Jul;2(2):165-71. doi: 10.1159/000345278.
  • Tigue CC, McKoy JM, Evens AM, Trifilio SM, Tallman MS, Bennett CL. Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant. 2007 Aug;40(3):185-92.
  • Johnson DW, Herzig KA. Clinical appearance of a post-transplant lymphoma following G-CSF therapy. Nephrol Dial Transplant. 1999 Jul;14(7):1806-7.
Toplam 41 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular İç Hastalıkları
Bölüm Original Articles
Yazarlar

Emel Isiktas Sayilar 0000-0002-8824-6560

Alparslan Ersoy 0000-0002-0710-0923

Sedat Çelikçi 0000-0002-9731-1424

Yavuz Ayar 0000-0003-4607-9220

Fahir Özkalemkaş 0000-0001-9710-134X

Vildan Ozkocaman 0000-0003-0014-7398

Rıdvan Ali 0000-0001-6486-3399

Yayımlanma Tarihi 29 Ocak 2020
Gönderilme Tarihi 4 Aralık 2019
Kabul Tarihi 10 Ocak 2020
Yayımlandığı Sayı Yıl 2020 Cilt: 2 Sayı: 1

Kaynak Göster

EndNote Isiktas Sayilar E, Ersoy A, Çelikçi S, Ayar Y, Özkalemkaş F, Ozkocaman V, Ali R (01 Ocak 2020) Granulocyte colony-stimulating factor usage in drug-induced neutropenia after kidney transplantation: a single-center experience. Turkish Journal of Internal Medicine 2 1 11–18.

Cited By

Management of drug‐induced neutropenia, thrombocytopenia, and anaemia after solid organ transplantation: A comprehensive review
Journal of Clinical Pharmacy and Therapeutics
https://doi.org/10.1111/jcpt.13775
 Kapak Resmi İndir

e-ISSN: 2687-4245 

Turkish Journal of Internal Medicine, hosted by Turkish JournalPark ACADEMIC, is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

by-nc-nd.png
2023 -TJIM.org